HNHS(SH:600156)2024-04-25 08:44Financial Performance - The company's operating revenue for Q1 2024 was ¥187,115,167.55, representing a year-on-year increase of 16.15%[5] - Total revenue for Q1 2024 was CNY 187,115,167.55, an increase of 16.2% compared to CNY 161,094,791.97 in Q1 2023[17] - Total operating costs for Q1 2024 were CNY 200,248,513.50, up 12.9% from CNY 177,376,421.72 in Q1 2023[17] - Net loss for Q1 2024 was CNY 14,168,523.76, compared to a net profit of CNY 10,283,675.91 in Q1 2023[17] - Basic and diluted earnings per share were both -¥0.0316, reflecting a decline of 180.00% year-on-year[5] - Basic and diluted earnings per share for Q1 2024 were both CNY -0.0316, down from CNY 0.0395 in Q1 2023[18] Cash Flow - The net cash flow from operating activities was -¥23,902,966.17, indicating a negative cash flow situation[5] - Cash flow from operating activities for Q1 2024 showed a net outflow of CNY -23,902,966.17, compared to CNY -12,587,846.97 in Q1 2023[20] - Cash flow from financing activities totaled $1,412,395.83, a decrease from $16,835,486.10 in the previous period[21] - Net cash flow from financing activities was -$1,412,395.83, compared to -$6,835,486.10 last year[21] - The net increase in cash and cash equivalents was -$23,352,148.37, down from -$49,953,349.02 in the prior year[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥881,500,159.26, down 6.34% from the end of the previous year[5] - Total assets as of March 31, 2024, were CNY 881,500,159.26, down from CNY 941,193,995.35 at the end of 2023[13] - Total liabilities decreased to CNY 430,142,978.18 in Q1 2024 from CNY 475,668,290.51 in Q4 2023[13] - Current assets totaled CNY 352,478,489.95, a decrease from CNY 404,500,190.83 at the end of 2023[13] - The equity attributable to shareholders decreased to ¥451,053,840.41, a reduction of 2.74% compared to the previous year[6] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,762[10] Research and Development - Research and development expenses for Q1 2024 were CNY 2,236,808.04, compared to CNY 1,979,331.11 in Q1 2023, reflecting a 13% increase[17] Non-Recurring Items - Non-recurring losses totaled -¥3,394,749.00, primarily due to fluctuations in stock prices and other operational factors[7] Cash and Cash Equivalents - The company reported a decrease in cash and cash equivalents to CNY 124,415,816.68 from CNY 147,766,673.20 at the end of 2023[13] - The ending balance of cash and cash equivalents was $121,859,210.15, compared to $82,998,489.02 at the end of the previous year[21] - The beginning balance of cash and cash equivalents was $145,211,358.52, an increase from $132,951,838.04 year-over-year[21] Return on Equity - The weighted average return on equity was -2.78%, a decrease of 6.30 percentage points year-on-year[5]